Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Evommune (NYSE:EVMN) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
Evommune (NYSE:EVMN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $42.00 price target on the stock.
Evommune (NYSE:EVMN) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.
Evommune (NYSE:EVMN) was given a new $40.00 price target on by analysts at Raymond James Financial, Inc..